全文获取类型
收费全文 | 3360748篇 |
免费 | 233503篇 |
国内免费 | 8740篇 |
专业分类
耳鼻咽喉 | 46562篇 |
儿科学 | 112356篇 |
妇产科学 | 94049篇 |
基础医学 | 471794篇 |
口腔科学 | 93319篇 |
临床医学 | 304135篇 |
内科学 | 649483篇 |
皮肤病学 | 81221篇 |
神经病学 | 269671篇 |
特种医学 | 132525篇 |
外国民族医学 | 993篇 |
外科学 | 503665篇 |
综合类 | 66090篇 |
现状与发展 | 6篇 |
一般理论 | 1181篇 |
预防医学 | 254892篇 |
眼科学 | 76446篇 |
药学 | 251673篇 |
15篇 | |
中国医学 | 6936篇 |
肿瘤学 | 185979篇 |
出版年
2019年 | 25650篇 |
2018年 | 39014篇 |
2017年 | 31120篇 |
2016年 | 34912篇 |
2015年 | 40043篇 |
2014年 | 52982篇 |
2013年 | 77029篇 |
2012年 | 106443篇 |
2011年 | 108410篇 |
2010年 | 64826篇 |
2009年 | 63041篇 |
2008年 | 99471篇 |
2007年 | 106262篇 |
2006年 | 108211篇 |
2005年 | 110330篇 |
2004年 | 107609篇 |
2003年 | 100317篇 |
2002年 | 93210篇 |
2001年 | 160902篇 |
2000年 | 163898篇 |
1999年 | 138996篇 |
1998年 | 37192篇 |
1997年 | 32574篇 |
1996年 | 32686篇 |
1995年 | 33549篇 |
1994年 | 30575篇 |
1993年 | 28643篇 |
1992年 | 109215篇 |
1991年 | 105655篇 |
1990年 | 102944篇 |
1989年 | 99711篇 |
1988年 | 91100篇 |
1987年 | 89087篇 |
1986年 | 83881篇 |
1985年 | 79610篇 |
1984年 | 58946篇 |
1983年 | 49616篇 |
1982年 | 28740篇 |
1981年 | 25393篇 |
1979年 | 52624篇 |
1978年 | 36472篇 |
1977年 | 31525篇 |
1976年 | 28583篇 |
1975年 | 31460篇 |
1974年 | 37183篇 |
1973年 | 35400篇 |
1972年 | 33546篇 |
1971年 | 31338篇 |
1970年 | 28866篇 |
1969年 | 27792篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
2.
Purnima Gogoi Geetika Kaur Nikhlesh K Singh 《World journal of gastroenterology : WJG》2022,28(46):6497-6511
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology. 相似文献
3.
4.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
5.
6.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
7.
8.
9.
In 2019, the scientists who discovered how cells sense and adapt to oxygen availability were awarded the Nobel Prize. This elegant sensing pathway is conserved throughout evolution, and it underpins the physiology and pathology that we, as clinicians in anaesthesia and critical care, encounter on a daily basis. The purpose of this review is to bring hypoxia-inducible factor, and the oxygen-sensing pathway as a whole, to the wider clinical community. We describe how this unifying mechanism was discovered, and how it orchestrates diverse changes such as erythropoiesis, ventilatory acclimatisation, pulmonary vascular remodelling and altered metabolism. We explore the lessons learnt from genetic disorders of oxygen sensing, and the wider implications in evolution of all animal species, including our own. Finally, we explain how this pathway is relevant to our clinical practice, and how it is being manipulated in new treatments for conditions such as cancer, anaemia and pulmonary hypertension. 相似文献
10.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献